



**Supplementary Fig. 4.** Increase of cell survival was reduced by inhibition of *ABCG2* expression in cancer cells with acquired cisplatin resistance induced by TCDD pretreatment. **(A)** Real time RT-PCR analysis indicates a reduction in *ABCG2* expression in LS180 cells 48 hr after transfection with the *ABCG2* siRNA (30 nM), compared to the negative control siRNA (30 nM). Human GAPDH was used as an internal control. **(B)** Cell survival of LS180 cells transfected with the *ABCG2* siRNA was assessed by the MTT assay. Survival rate of untreated, non-transfected cells was considered as 1.0. After transfection for 12 hr, LS180 cells were pretreated with 10 nM TCDD for one day and then treated with 10 µg/mL cisplatin for 12 hr. Data are presented as the mean ± SD from three independent experiments performed in duplicate. \*\* $P < 0.01$ ; CTL, control; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; CDDP, cisplatin.